Business, energy, technology, markets and global industry news from Business News Today

gadolinium-based contrast agents

PharmaDeviceNews gadolinium-based contrast agents
Medical Devices & Diagnostics

GE HealthCare’s LUMINA trial could test whether manganese MRI contrast is finally ready for the mainstream

GE HealthCare has dosed the first patient in its LUMINA trial for mangaciclanol. Read why this MRI contrast milestone could reshape imaging markets.

Read More
Guerbet expands gadopiclenol into neonates as FDA backs half-dose MRI contrast strategy
Medical Devices & Diagnostics

What Guerbet’s pediatric gadopiclenol label expansion reveals about the future of MRI contrast agents

FDA approval expands Guerbet’s gadopiclenol into neonates, reinforcing half-dose MRI contrast strategies. Find out what this changes for pediatric imaging.

Read More
Representative image of a neonatal magnetic resonance imaging scan in a hospital setting, illustrating how low-dose gadolinium contrast agents like Vueway gadopiclenol are reshaping pediatric MRI safety and regulatory decision-making in Europe.
Medical Devices & Diagnostics

CHMP backs Vueway pediatric expansion, signaling a cautious but meaningful shift in neonatal MRI contrast use

Bracco Imaging S.p.A. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion supporting the use of Vueway gadopiclenol in pediatric patients from birth. The recommendation extends an existing European Union authorization and places the macrocyclic gadolinium-based contrast agent into one of the

Read More